CorMedix (CRMD) reported Q4 2025 net revenue of USD 128.6 million, including USD 91.2 million from DefenCath sales and USD 37.4 million from the Melinta portfolio; total operating expenses were USD 48.2 million, up 182%. Q4 net income was USD 14.0 million (diluted EPS USD 0.16) and adjusted EBITDA was USD 77.2 million. For FY 2025, total revenue was USD 311.7 million, including USD 258.8 million in DefenCath net sales and USD 52.9 million in net revenue from the legacy Melinta portfolio; net income was USD 163.0 million (diluted EPS USD 2.04). Cash and short-term investments (excluding restricted cash) were USD 148.5 million at Dec. 31, 2025. CorMedix reiterated 2026 guidance for net revenue of USD 300–320 million and adjusted EBITDA of USD 100–125 million, said its board approved a share repurchase program of up to USD 75 million, and expects Phase 3 ReSPECT data for REZZAYO prophylaxis in Q2 2026; the Phase 3 taurolidine/heparin catheter lock study in TPN patients continues enrolling with targeted completion in H1 2027. The company said Q4 tax expense was primarily tied to utilization of deferred tax assets related to anticipated future use of NOL carryforwards.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050730PRIMZONEFULLFEED9666256) on March 05, 2026, and is solely responsible for the information contained therein.
Comments